Exploring the Potential Applications of EDIL3: A Drug Target and Biomarker

Target Name: EDIL3

NCBI ID: G10085

EDIL3

Other Name(s): EDIL3_HUMAN | EGF like repeats and discoidin domains 3 | Developmentally-regulated endothelial cell locus 1 protein | Developmental endothelial locus-1 | DEL1 | developmentally-regulated endothelial cell locus 1 protein | developmental endothelial locus-1 | EDIL3 variant 1 | EGF like repeats and discoidin domains 3, transcript variant 1 | integrin-binding protein DEL1 | Integrin-binding protein DEL1 | EGF-like repeats and discoidin I-like domains 3 | EGF-like repeat and discoidin I-like domain-containing protein 3 | EGF-like repeat and discoidin I-like domain-containing protein 3 (isoform 1)

Exploring the Potential Applications of EDIL3: A Drug Target and Biomarker

EDIL3 (endoplasmic reticulum-associated protein-3) is a protein that is expressed in various tissues and cell types in the human body. Its primary function is to regulate the retrieval of intracellular protein structures from the endoplasmic reticulum (ER) and to modulate the trafficking of these structures to the cytosol for various cellular processes. EDIL3 has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Disease-Related Applications of EDIL3

EDIL3 has been shown to be involved in the development and progression of various diseases. Its functions in regulating intracellular protein trafficking have been implicated in the pathogenesis of several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Neurodegenerative Disorders

EDIL3 has been shown to be involved in the development and progression of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the formation of aggregates of toxic proteins, including tau, beta-amyloid, and neurofilament tangles.

EDIL3 has been shown to regulate the trafficking of beta-amyloid to the endoplasmic reticulum, which is thought to contribute to the formation of beta-amyloid plaques in the brain. It has also been shown to play a role in the regulation of neurotransmitter synthesis and release, which may be important in the pathogenesis of neurodegenerative disorders.

Cancer

EDIL3 has also been shown to be involved in the development and progression of cancer. Its functions in regulating intracellular protein trafficking have been implicated in the regulation of cell signaling pathways, which are critical for the growth and survival of cancer cells.

EDIL3 has been shown to play a role in the regulation of mitochondrial function, which is critical for the growth and survival of cancer cells. It has also been shown to regulate the production of reactive oxygen species (ROS), which can contribute to the development of oxidative stress in cancer cells.

Autoimmune Diseases

EDIL3 has also been shown to be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. These disorders are characterized by the production of autoantibodies and the damage of self-antigens, including proteins that are expressed in various tissues and cell types.

EDIL3 has been shown to play a role in the regulation of immune cell function, which is critical for the development and progression of autoimmune diseases. It has also been shown to regulate the production of pro-inflammatory cytokines, which can contribute to the development of autoimmune diseases.

Potential Therapeutic Applications of EDIL3

The potential therapeutic applications of EDIL3 are vast and varied. Its functions in regulating intracellular protein trafficking have been implicated in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

EDIL3 has been shown to be a potential drug target for various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its functions in regulating beta-amyloid and neurofilament tangles have been implicated in the development and progression of these disorders.

EDIL3 has also been shown to be a potential biomarker for neurodegenerative disorders. Its expression has been shown to be reduced in individuals with neurodegenerative disorders, and its levels have been shown to be increased in individuals with these disorders.

EDIL3 has also been shown to be involved in the regulation of cancer cell growth and survival. Its functions in regulating intracellular

Protein Name: EGF Like Repeats And Discoidin Domains 3

Functions: Promotes adhesion of endothelial cells through interaction with the alpha-v/beta-3 integrin receptor. Inhibits formation of vascular-like structures. May be involved in regulation of vascular morphogenesis of remodeling in embryonic development

The "EDIL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDIL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets